Tan You-Wen, Shi Yi-Chun
Department of Hepatology, The Third Hospital of Zhenjiang Affiliated Jiangsu University, Zhenjiang 212003, Jiangsu Province, China.
World J Clin Cases. 2022 Sep 16;10(26):9241-9253. doi: 10.12998/wjcc.v10.i26.9241.
Hematopoietic stem cell transplantation (HSCT)-sinusoidal obstruction syndrome (SOS), also known as veno-occlusive disease, is a clinical syndrome characterized by symptoms, such as right upper quadrant pain, jaundice, fluid retention, and hepatomegaly, and is caused by pre-treatment-related hepatotoxicity during the early stages after HSCT. Clinical diagnosis of HSCT-SOS is based on the revised Seattle or Baltimore standards. The revised standard by the European Society for Bone Marrow Transplantation in 2016 has good practicability and can be used in combination with these two standards. Eight studies have shown the value of liver stiffness measurement (LSM) in the early diagnosis of HSCT-SOS. Four studies investigated LSM specificity and sensitivity for the early diagnosis of HSCT-SOS. LSM can distinguish SOS from other post-HSCT complications, enabling a clear differential diagnosis. It has been shown that median LSM of patients with SOS is significantly higher than that of patients with other treatment-related liver complications (., acute cholecystitis, cholangitis, antifungal drug-related liver injury, liver graft-versus-host disease, isolated liver biochemical changes, and fulminant Epstein Barr virus related hepatitis reactivation). Therefore, the above data confirmed the utility of LSM and strongly suggested that LSM improves the positive predictive value of the SOS diagnostic clinical score after allogeneic HSCT. Early diagnosis of SOS is beneficial in preventing severe HSCT complications.
造血干细胞移植(HSCT)-肝窦阻塞综合征(SOS),也称为静脉闭塞性疾病,是一种临床综合征,其特征为右上腹疼痛、黄疸、液体潴留和肝肿大等症状,由HSCT后早期的预处理相关肝毒性引起。HSCT-SOS的临床诊断基于修订后的西雅图或巴尔的摩标准。2016年欧洲骨髓移植学会修订的标准具有良好的实用性,可与这两个标准结合使用。八项研究显示了肝脏硬度测量(LSM)在HSCT-SOS早期诊断中的价值。四项研究调查了LSM对HSCT-SOS早期诊断的特异性和敏感性。LSM可将SOS与其他HSCT后并发症区分开来,实现明确的鉴别诊断。研究表明,SOS患者的LSM中位数显著高于其他治疗相关肝脏并发症(如急性胆囊炎、胆管炎、抗真菌药物相关肝损伤、肝移植物抗宿主病、孤立性肝脏生化改变以及暴发性EB病毒相关肝炎再激活)患者的LSM中位数。因此,上述数据证实了LSM的实用性,并强烈表明LSM提高了异基因HSCT后SOS诊断临床评分的阳性预测价值。SOS的早期诊断有利于预防严重的HSCT并发症。